SCHEMBL23329192

SCHEMBL23329192

CSc1ccc(-c2[nH]nnc2C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.39
MAPK14 Q16539 4/20 0.35
GCGR P47871 3/20 0.35
MAPK13 O15264 2/20 0.35
ALOX5 P09917 2/20 0.35
MAPK12 P53778 2/20 0.35
MAPK11 Q15759 2/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
LCK P06239 1/20 0.35
RET P07949 1/20 0.35
PRKACA P17612 1/20 0.35
RPS6KB1 P23443 1/20 0.35
MATK P42679 1/20 0.35
FRK P42685 1/20 0.35
MAPK9 P45984 1/20 0.35
CSNK1A1 P48729 1/20 0.35
CSNK1D P48730 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16473172 0.80 LMNA (0.38) NISCHLMNANPC1RAB9A
SCHEMBL16478914 0.77 ALDH1A1 (0.39) MAPK14LMNANPC1TSHRRAB9A
SCHEMBL14307558 0.77 MAPK14 (0.40) MAPK14GCGRMAPK13MAPK12MAPK11
SCHEMBL23328982 0.74 RAB9A (0.47) NISCHMAPK14GCGRMAPK13MAPK12
SCHEMBL27034774 0.73 BRD4 (0.44) LMNANPC1TSHRRAB9AKDM4E
SCHEMBL15302748 0.71 ALDH1A1 (0.44) PTGS2LMNAMAPK1TSHRKDM4E
SCHEMBL17424258 0.69 LTA4H (0.42) LMNAMAPK1NPC1RAB9AKDM4E
SCHEMBL411509 0.69 CYP1A1 (0.46) MAPK1KDM4EALDH1A1
SCHEMBL7157504 0.68 NISCH (0.40) NISCHMAPK14GCGRMAPK13ALOX5
SCHEMBL14519409 0.67 MAPK14 (0.46) MAPK14GCGRMAPK13ALOX5MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO NISCH 994/4885MAPK14 2258/4885GCGR 841/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO NISCH 994/4885MAPK14 2258/4885GCGR 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.